Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma
Cargando...
Archivos
Fecha
2018
Título de la revista
Publicado en
Journal of Neuro-Oncology, 1573-7373, Vol 136, Num 2, 2018, pag 363-371
Publicado por
Springer
URL de la fuente
ISSN de la revista
Título del volumen
Resumen
Descripción
Abstract
Epilepsy is a common symptom in patients with glioblastoma (GB). 213 patients with GB from RedLANO follow-up registry were included. All patients underwent surgery, if feasible, followed by chemoradiation based on temozolomide (Stupp platform). Information was recorded regarding demographics, seizure timing, anti-epileptic drugs (AEDs), dosage, time to next seizure, total seizures in 6 months, and main side effects of AEDs. The relationship between epilepsy treatment and overall survival (OS) was evaluated. Mean age was 53 years old and 56.8% were male. Seventy-eight patients (37%) were treated with levetiracetam (LEV), 27% were given another AED and 36% did not require any AED. Choice of AED was not associated with age (p = 0.67), performance status (p = 0.24) or anatomic tumor site (p = 0.34). Seizures and AED requirement were greater in those having primary GB (p = 0.04). After starting an AED, the mean time until next crisis was 9.9 days (SD ± 6.3), which was shorter in those receiving LEV (p = 0.03); mean number of seizures during the first 3 and 6 months were 2.9 and 4, respectively. Most patients treated with LEV (n = 46) required less than two medication adjustments compared to those treated with other AEDs (p = 0.02). Likewise, less patients exposed to LEV required a coadjuvant drug (p = 0.04). Additionally, patients receiving LEV had significantly less adverse effects compared to patients treated with another AED. OS was significantly higher in the group treated with LEV compared to other AEDs (25.5 vs. 17.9 months; p = 0.047). Patients treated with LEV had better seizure control and longer OS compared to other AEDs.
Palabras clave
Keywords
Efficacy, Safety, Antiepileptic drugs, Hispanic, Glioblastoma
Temáticas
Anticonvulsivantes
Evaluación de medicamentos
Pirrolidinonas
Evaluación de medicamentos
Pirrolidinonas